Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Stokes Family Office LLC

Stokes Family Office LLC lessened its stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 22.3% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 7,609 shares of the medical research company's stock after selling 2,190 shares during the period. Stokes Family Office LLC's holdings in Charles River Laboratories International were worth $1,405,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Virtu Financial LLC purchased a new stake in shares of Charles River Laboratories International in the 3rd quarter valued at $601,000. JPMorgan Chase & Co. boosted its stake in shares of Charles River Laboratories International by 21.6% in the third quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company's stock valued at $95,086,000 after purchasing an additional 85,759 shares during the period. State Street Corp boosted its stake in shares of Charles River Laboratories International by 2.0% in the third quarter. State Street Corp now owns 2,130,279 shares of the medical research company's stock valued at $419,601,000 after purchasing an additional 41,421 shares during the period. Janus Henderson Group PLC grew its holdings in shares of Charles River Laboratories International by 7.6% in the third quarter. Janus Henderson Group PLC now owns 46,018 shares of the medical research company's stock valued at $9,064,000 after purchasing an additional 3,268 shares in the last quarter. Finally, Neo Ivy Capital Management acquired a new stake in Charles River Laboratories International during the 3rd quarter worth approximately $966,000. Institutional investors and hedge funds own 98.91% of the company's stock.

Remove Ads

Insider Activity at Charles River Laboratories International

In related news, EVP Joseph W. Laplume sold 4,400 shares of Charles River Laboratories International stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $162.50, for a total value of $715,000.00. Following the transaction, the executive vice president now directly owns 20,013 shares in the company, valued at $3,252,112.50. This trade represents a 18.02 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, COO Birgit Girshick acquired 1,514 shares of the company's stock in a transaction on Thursday, February 20th. The stock was purchased at an average cost of $164.63 per share, for a total transaction of $249,249.82. Following the completion of the purchase, the chief operating officer now directly owns 55,058 shares in the company, valued at $9,064,198.54. This trade represents a 2.83 % increase in their position. The disclosure for this purchase can be found here. 1.30% of the stock is currently owned by insiders.

Charles River Laboratories International Stock Performance

Shares of CRL stock traded up $1.94 during mid-day trading on Friday, hitting $167.29. 1,638,932 shares of the stock were exchanged, compared to its average volume of 725,184. Charles River Laboratories International, Inc. has a 12-month low of $150.79 and a 12-month high of $273.57. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. The stock has a market capitalization of $8.55 billion, a price-to-earnings ratio of 1,115.26, a P/E/G ratio of 4.54 and a beta of 1.45. The stock's fifty day simple moving average is $166.11 and its two-hundred day simple moving average is $183.71.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, topping the consensus estimate of $2.50 by $0.16. The company had revenue of $1 billion for the quarter, compared to analyst estimates of $983.63 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The firm's revenue was down 1.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.46 earnings per share. On average, analysts forecast that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Analysts Set New Price Targets

CRL has been the topic of a number of recent research reports. Bank of America cut their price objective on Charles River Laboratories International from $220.00 to $210.00 and set a "neutral" rating on the stock in a research report on Friday, December 13th. UBS Group restated a "neutral" rating and set a $185.00 price target (down previously from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. Barclays decreased their price objective on Charles River Laboratories International from $205.00 to $166.00 and set an "equal weight" rating for the company in a research note on Tuesday, February 18th. Morgan Stanley cut their target price on shares of Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating on the stock in a research note on Wednesday, February 5th. Finally, Redburn Atlantic upgraded shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 price target for the company in a research note on Monday, March 3rd. One equities research analyst has rated the stock with a sell rating and sixteen have assigned a hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $189.77.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).